The company granted stock options to purchase an aggregate of 208,350 shares of Nurix common stock and restricted stock unit awards (RSUs) representing an aggregate of 272,850 shares of Nurix common ...

The event will be webcast live and may be accessed via a link in the Investors section of the Nurix website. The archived webcast will be available for 30 days after the event. About Nurix ...

Nurix Therapeutics has a fifty-two week low of $8.11 and a fifty-two week high of $29.56. The firm has a market cap of $1.43 billion, a price-to-earnings ratio of -6.53 and a beta of 2.14.

Several brokerages have updated their recommendations and price targets on shares of Nurix Therapeutics (NASDAQ: NRIX) in the last few weeks: NRIX opened at $19.71 on Monday. The business has a 50 ...

SAN FRANCISCO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...

Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $0.77 per share a year ago.

Just because a business does not make any money, does not mean that the stock will go down. For example, Nurix Therapeutics (NASDAQ:NRIX) shareholders have done very well over the last year, with the ...

8 analysts have expressed a variety of opinions on Nurix Therapeutics (NASDAQ:NRIX) over the past quarter, offering a diverse set of opinions from bullish to bearish. In the table below ...